NR3C2 and atrial fibrillation: As further evidence of the importance of aldosterone and mineralocorticoid receptors in the pathogenesis of AF, mineralocorticoid receptor antagonists (MRAs) have been shown to reduce the risk of new-onset AF in predominantly European populations with systolic heart failure [21], [22], [23].